Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: A meta-analysis

Objective: The aim of this study was to investigate the clinical value of urine Prostate cancer antigen 3 (PCA3) test in the diagnosis of prostate cancer by pooling the published data. Methods: The clinical trials about urine PCA3 test in the diagnosis of prostate cancer were searched in the PubMed (January, 1966 July, 2014). Cochrane library (Section 3, 2013), CNKI (March, 1994 July, 2014). All relevant prospective studies of urine PCA3 test in the diagnosis of prostate cancer were screened. The aggregated sensitivity, specificity, positive likely hood ratio (+LR), negative likely hood ratio ( LA), diagnosis odds ratio (DOR) and area under the area under curve (AUC) were calculated by using Meta-disc 1.4 and STATA 11.0 statistic software. Results: Finally, a total of 13 trials including 3245 subjects were included in this meta-analysis. The pooled sensitivity, specificity, +LR, LA, DOA and AUC were 0.62 (95% confidence interval [CI]: 0.59-0.65), 0.75 (95% CI: 0.73-0.76), 6.16 (95% CI: 3.39-11.21), 0.50(95% CI: 0.43-0.59), 5.49(95% CI: 3.76-8.019) and 0.75 (95% CI: 0.71-0.78), respectively. Conclusion: Urine PCA3 test has acceptable sensitivity and specificity in the diagnosis of prostate cancer, which can be used as non-invasive method for diagnosis of prostate cancer.